In vivo human brain expression of histone deacetylases in bipolar disorder

Chieh-En J. Tseng,1 Tonya M. Gilbert,1 Mary C. Catanese,1 Baileigh G. Hightower,1 Amy T. Peters,2 Anjali J. Parmar,1 Minhae Kim,1 Changning Wang,1 Joshua L. Roffman1,2, Hannah E. Brown,3 Roy H. Perlis,2,4 Nicole R. Zürcher,6 and Jacob M. Hooker6

Abstract
The etiology of bipolar disorder (BD) is unknown and the neurobiological underpinnings are not fully understood. Both genetic and environmental factors contribute to the risk of BD, which may be linked through epigenetic mechanisms, including those regulated by histone deacetylase (HDAC) enzymes. This study measures in vivo HDAC expression in individuals with BD for the first time using the HDAC-specific radiotracer [11C]Martinostat. Eleven participants with BD and 11 age- and sex-matched control participants (CON) completed a simultaneous magnetic resonance–positron emission tomography (MR-PET) scan with [11C]Martinostat. Lower [11C]Martinostat uptake was found in the right amygdala of BD compared to CON. We assessed uptake in the dorsolateral prefrontal cortex (DLPFC) to compare previous findings of lower uptake in the DLPFC in schizophrenia and found no group differences in BD. Exploratory whole-brain voxelwise analysis showed lower [11C]Martinostat uptake in the bilateral thalamus, orbitofrontal cortex, right hippocampus, and right amygdala in BD compared to CON. Furthermore, regional [11C]Martinostat uptake was associated with emotion regulation in BD in fronto-limbic areas, which aligns with findings from previous structural, functional, and molecular neuroimaging studies in BD. Regional [11C]Martinostat uptake was associated with attention in BD in fronto-parietal and temporal regions. These findings indicate a potential role of HDACs in BD pathophysiology. In particular, HDAC expression levels may modulate attention and emotion regulation, which represent two core clinical features of BD.

Introduction
The etiology and underlying pathology of bipolar disorder (BD) are poorly understood, and their elucidation is complicated by misdiagnosis due to overlapping symptoms with other neuropsychiatric disorders including schizophrenia, unipolar depression, and impulse control1. Polygenic risk has explained some of the heritability of BD, which is estimated at ~60–80%2–4, and environmental factors including childhood trauma and life events contribute additional risk5. The connection between these two variables—genetic and environmental risk—has been difficult to assess but may be explained at a molecular level by epigenetic mechanisms. Moreover, dysregulation of gene transcription in animal models of neuropsychiatric disorders is well-established and in part can be attributed to epigenetic enzymes, including histone deacetylases (HDACs)6,7.

Genetic association and clinical pharmacology have been used to identify a potential role for HDACs in BD. For example, a recent systematic analysis of genome-wide association study (GWAS) data incorporating gene pathway analysis, found that HDAC2 may be linked to increased genetic risk for BD through its involvement in the development of the amygdala, nucleus accumbens and hippocampus8. Moreover, pharmacological treatments for
BD act on HDACs. Specifically, valproic acid (VPA) is an HDAC inhibitor\textsuperscript{9}, lithium downregulates HDAC1\textsuperscript{10}, and lamotrigine increases histone acetylation levels in vitro\textsuperscript{11}. Additionally, hyper-activity was reduced by HDAC inhibition in preclinical models of mania\textsuperscript{12,13}. Collectively, these observations beg the question of whether HDACs may represent a direct mechanistic link to BD.

Brain pathology has implicated a potential association between HDACs and BD in specific brain regions. For example, in the dorsolateral prefrontal cortex (DLPFC) and caudate, no differences were detected in HDAC1 or HDAC2 mRNA transcript levels between BD donor samples compared to controls\textsuperscript{14}, while in the hippocampus SO-CA2/3 region, HDAC1 mRNA transcript levels were ~3-fold lower in BD donor samples compared to controls\textsuperscript{15}. However, pathology studies are fraught with classical challenges in interpreting results from post-mortem tissue, including the analysis of a limited number of brain regions across studies with varying methodology.

Evidence from rodent studies also suggest involvement of HDACs in relation to BD-associated behavior or treatment. For example, anti-manic effects of HDAC inhibition are suggested to be related to the amygdala, striatum, and prefrontal cortex, but not the hippocampus in rats\textsuperscript{12}. Also, treatment of lithium or the HDAC inhibitor, sodium butyrate, increased the levels of acetylation on histone H3, an indirect measure of altered HDAC levels and/or activity in the amygdala in rats\textsuperscript{16}. Additionally, HDAC inhibition in the basolateral amygdala decreased fear extinction and increased memory consolidation in rodents\textsuperscript{17}. However, to the best of our knowledge, HDAC expression has not been examined in the amygdala in humans.

The amygdala represents an important neural substrate in BD due to its role in mood and emotion regulation\textsuperscript{18–21}. Extant neuroimaging studies demonstrate structural and functional abnormalities of the amygdala in BD\textsuperscript{22–24}, as well as within broader fronto-limbic neural circuitry\textsuperscript{18,19}, critical for top-down regulation of emotion and attentional functions. Notably, emotion dysregulation and attention disturbance are present in BD during both acute manic and depressive episodes but also persist during periods of relative euthymia\textsuperscript{25,26}. Given that current medications do not adequately improve these processes for many patients with BD\textsuperscript{27}, molecular strategies to improve emotion regulation and attention are acutely needed. The implication of HDACs in emotion and attention has been shown in both rodents\textsuperscript{12,28–35} and humans\textsuperscript{36,37}, however, the relationship between HDAC expression and these clinical features has not been examined in patients with BD.

To fill the translational gap that exists between genetic, pharmacological and pathological studies demonstrating roles for HDACs in BD, we measured in vivo HDAC distribution and relative expression levels in BD compared to healthy age- and sex-matched controls (CON) using the HDAC-specific radiotracer \textsuperscript{[11C]}Martinostat\textsuperscript{38–41} and positron emission tomography (PET). Our primary hypothesis was that HDACs would be differentially expressed in the amygdala of BD compared to CON with potential right lateralization, based on previous functional imaging findings of amygdalar activation\textsuperscript{42} and right hemisphere disturbances often reported in BD\textsuperscript{43}. In a previous study, relative in vivo HDAC expression was shown to be lower in the DLPFC in patients with schizophrenia compared to unaffected controls\textsuperscript{36}. This finding aligned with results from a separate large-scale postmortem study\textsuperscript{14}, which also found no differences in this region in BD. Thus, we further hypothesized that relative in vivo HDAC expression in the DLPFC would not be different between BD compared to CON. We also conducted voxelwise analyses to assess HDAC expression across the entire brain in an exploratory follow-up. In addition, to understand the clinical implications of HDACs in BD, we investigated the relationships between HDAC expression, emotion dysregulation, and attention disturbance, as measured by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus cognitive battery (MCCB)\textsuperscript{44–47}.

**Methods**

**Study design**

The main goal of this study was to measure in vivo HDAC expression using \textsuperscript{[11C]}Martinostat and simultaneous MR-PET neuroimaging. This study was approved by the Partners HealthCare Institutional Review Board (IRB) and the Massachusetts General Hospital (MGH) Radioactive Drug Research Committee. All participants provided written informed consent according to the Declaration of Helsinki. Participants underwent a physical examination by a licensed physician or nurse practitioner in order to determine study eligibility and to record medical history, medication use and smoking status. Eleven participants with BD and 11 age- and sex-matched CON (Table 1) completed a \textsuperscript{[11C]}Martinostat MR-PET scan at the Athinoula A. Martinsos Center for Biomedical Imaging. Imaging studies were not blinded to diagnosis, and no outliers were excluded (as assessed via the ROUT method\textsuperscript{48} in GraphPad Prism version 8; the ROUT method combines robust nonlinear regression and outlier detection based on false discovery rate to determine outliers).

**Study participants**

BD and CON were group matched for age and sex. In order to obtain group matched CON, the CON were pooled from two studies. Participants were physically healthy as determined by medical history and a physical examination. Patients with BD met DSM-IV criteria for
Table 1 Demographic characteristics, medication, administered radiotracer dose, and cognitive metrics of study participants.

| Demographic or cognitive metric | Bipolar | Control | p-value |
|--------------------------------|---------|---------|---------|
| Age (year)                     | 38.2±15.5 | 38.4±15.3 | 0.91 |
| Sex (M/F)                      | 4/7      | 4/7     | >0.999 |
| Body mass index                | 31.4±8.9 | 26.0±4.3 | 0.24 |
| Smoking status (%)             | 0        | 0       | –      |
| Parental socioeconomic index\(^a\) | 2.3±0.8 | 3.1±1.1 | 0.06 |
| Handedness (L/R)\(^b\)         | 1/10     | 0/9     | >0.999 |
| Lithium/lamotrigine (%)        | 55       | 0       | –      |
| Antipsychotics (%)             | 73       | 0       | –      |
| Chlorpromazine equivalent dose (mg/d) | 193.9±352.7 | – | – |
| Injected dose (mCi)            | 5.3±0.2  | 5.0±0.3 | 0.0008 |
| Injected mass (μg)             | 1.6±0.9  | 1.1±0.5 | 0.22 |
| Molar activity (mCi/nmol)      | 1.8±1.4  | 1.9±0.9 | 0.37 |
| MCCB speed of processing T-score | 50.8±16.9 | 52.4±11.3 | 0.75 |
| MCCB attention/vigilance T-score | 46.8±9.3 | 46.4±11.8 | 0.93 |
| MCCB working memory T-score    | 45.5±14.0 | 47.6±14.1 | 0.75 |
| MCCB verbal learning T-score   | 51.2±9.5  | 49.4±6.7 | 0.40 |
| MCCB visual learning T-score   | 52.8±14.8 | 58.3±10.4 | 0.32 |
| MCCB reasoning and problem solving T-score | 49.4±10.6  | 58.3±8.3 | 0.47 |
| MCCB emotion regulation T-score | 48.8±6.7  | 45.9±13.6 | 0.72 |
| MCCB overall composite T-score | 48.9±13.9 | 49.±13.5 | 0.87 |

* p values were determined by the Wilcoxon rank-sum test for all except sex and handedness for which a Fisher’s exact test was used. Values are reported as mean ± standard deviation unless otherwise stated. MCCB measurement and treatment research to improve cognition in schizophrenia (MATRICS) consensus cognitive battery.

\(^a\)The Hollingshead Four-Factor Index of Social Status\(^5\) was used to measure parental socioeconomic status (not available for 2 CON).

\(^b\)Handedness was not available for 2 CON.

BD 1 (n = 6) or BD 2 (n = 5). BD diagnosis was confirmed by the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) or clinician confirmation. CON had no history of major physical or neuropsychiatric illness (CON were from two studies that used different methods to determine history of neuropsychiatric illness: n = 9 determined by SCID-I, Non-Patient Edition (SCID-I/NP) and n = 2 by the Mini-International Neuropsychiatric Interview (MINI)). No participants included in this study were currently taking valproic acid, a well-known HDAC inhibitor. All psychotropic medications or hormone treatments were exclusionary for CON participants. Antipsychotic medications were permitted in BD and chlorpromazine (CPZ) equivalent doses\(^4\) were calculated. Six of 11 BD were taking lithium or lamotrigine, which have demonstrated potential inhibitory effects on HDACs in vitro\(^10,11\) (Table 1). BD medication usage is reported in Supplementary Table 1. Eligible participants were not using illicit drugs or recreational marijuana, confirmed by a urine drug screen on the day of the scan (Discover Plus Drug Test Card DIS-DOA-3124, American Screening Corp.). Furthermore, all participants met requirements for both MR and PET scanning safety regulations. Eligible female participants had a negative serum pregnancy test (Sure-Vue serum hCG-STAT, Fisher HealthCare) on the day of the scan.

Radiosynthesis of \([11C]\)Martinostat

\([11C]\)Martinostat was synthesized through reductive amination, followed by conversion into a hydroxamic acid in the presence of hydroxylamine and sodium hydroxide in accordance with cGMP guidelines as described in\(^39\). \([11C]\)Martinostat is a hydroxamic acid-based HDAC inhibitor containing an adamantyl group and radiolabeled with \(^{11}\)C.

MR-PET data acquisition

\([11C]\)Martinostat was injected through an intravenous catheter in the antecubital vein by a licensed nuclear medicine technologist. PET and MR images were acquired simultaneously on a 3T Siemens TIM Trio with a BrainPET insert. PET data were collected for 90 min post-injection. The intrinsic spatial resolution of PET in the center field-of-view was <3 mm\(^50\). For the MR data, an 8-channel head coil was used. A high-resolution T1-weighted anatomical scan, multi-echo magnetization prepared rapid acquisition gradient echo (MEMPRAGE) with prospective motion correction (using EPI-based volumetric navigators, vNavs), with TR = 2530 ms, TE [1-4] = 1.66 ms, 3.53 ms, 5.4 ms, 7.27 ms, FOV = 280 mm, flip angle = 7 deg, voxel size = 1 mm isotropic\(^51\) was acquired.

Cognitive assessment

Participants completed the MCCB\(^4,45\). The Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT)\(^52\): Managing Emotions subtest was used to assess emotion dysregulation (as in refs. \(^36,37\)). The Continuous Performance Test – Identical Pairs\(^53\) was used to assess sustained attention, which is often affected in BD\(^54\). MCCB T-scores were age- and sex-corrected. All participants with BD and 9 CON completed the MCCB within 1 month before or after the scan. Two CON were from a study that did not include the MCCB. One of the two CON was re-contacted and completed the MSCEIT within 2 years of the scan. The MSCEIT score has been reported to remain stable over a 5-year period\(^55\), therefore we expect the results to be stable with a 2-year time...
period between cognitive and PET data collection for this CON.

**MR data processing and analysis**

The MEMPRAGE images were reconstructed using FreeSurfer’s automated segmentation and parcellation (version 6.0; http://surfer.nmr.mgh.harvard.edu/). The regions of interest (ROI) for the amygdala in native space were defined using these segmentations and visually inspected. Volumes were corrected for estimated total intracranial volume (eTIV) (corrected as a ratio of volume/eTIV). Because previous morphometry MR imaging studies detected reduced volume in multiple regions of the frontal cortex as well as the amygdala, hippocampus, and thalamus in BD compared to CON, we investigated the relationship between volume and [11C] Martinostat uptake. Volumes of anatomical regions represented in posthoc regions showing differences in [11C] Martinostat uptake between groups, or in correlations with [11C] Martinostat uptake, were extracted using Freesurfer tools.

**PET data processing and analysis**

PET images were reconstructed using the Ordinary Poisson Ordered Subset Expectation Maximization 3D algorithm from prompt coincidences, corrected for normalization, dead time, isotope decay, photon attenuation, and expected random and scatter coincidences. MR-based attenuation correction was applied using Statistical Parametric Mapping (SPM)–based, pseudo–computed tomography. PET data were binned and reconstructed in units of SUV in 1.25 mm isotropic voxel size. SUV maps normalized by the whole-brain mean were generated from 60 to 90 min post radiotracer injection. There was no difference in mean whole-brain SUV between the two groups (BD mean ± standard deviation: 3.44 ± 0.73; CON mean ± standard deviation: 3.80 ± 0.73; U = 44, p = 0.30). Motion was assessed by calculating the absolute frame displacement between six 5-min frames of the PET window of interest (i.e. 60–90 min post radiotracer injection) and a reference frame. Motion estimates were not different between groups (BD mean ± standard deviation: 0.43 ± 0.45 mm; CON mean ± standard deviation: 0.45 ± 0.43 mm; U = 60, p > 0.999). The amount of motion is below the intrinsic spatial resolution of PET.

ROI analysis was used to quantify differences in [11C] Martinostat uptake between BD and CON. The left and right amygdala were selected as a priori ROIs based on evidence of structural and functional abnormalities in the amygdala in BD and lateralized amygdala functions. In order to account for the small size of the amygdala and possible PET signal spillover from neighboring tissue, we applied geometric transfer matrix (GTM), a region-based partial volume correction (PVC) method using PETSurfer tools available within FreeSurfer. The PVC SUVR values were extracted from the left and right amygdala in native space. The DLPFC was also selected as an a priori ROI based on previous findings in postmortem brain tissue of differences in HDAC2 mRNA expression in donors with schizophrenia but not donors with BD compared to controls. Individual SUVR maps were registered to MNI standard space and spatially smoothed at full width at half maximum (FWHM) 8 mm. The DLPFC SUVR values were extracted from MNI standard space with the same DLPFC ROI used previously in Gilbert et al. Furthermore, to comprehensively interrogate in vivo HDAC expression in BD, we also conducted exploratory voxelwise analyses (described below in Statistical analysis).

**Statistical analysis**

Wilcoxon rank-sum test was used to assess between-group differences in demographic scores, MCCB T-scores, [11C] Martinostat uptake (SUV/SUVR), and volumetric data. Between-group differences in the ROI analysis were assessed with residuals of SUVR values (in the amygdala and DLPFC) after controlling for age and sex using Matlab’s fit linear regression function.

A whole-brain voxelwise group comparison for [11C] Martinostat uptake between BD and CON was conducted using FSL’s FEAT (FMRIB software library, Oxford, UK; https://fsl.fmrib.ox.ac.uk/fsl/) with an unpaired t test, ordinary least squares (OLS) mixed-effects modeling, a significance threshold of Z > 2.3, and cluster correction of p_cluster < 0.05. Age and sex were added to the model as regressors of no interest. Whole-brain voxelwise analyses correlating [11C] Martinostat uptake with MCCB emotion regulation and attention T-scores in BD was conducted using FSL’s FEAT (Z > 2.3, p_cluster < 0.05), with age and sex added to the model as regressors of no interest.

Spearman’s rank-order correlation was used to correlate: (1) right amygdalar SUVR residuals with CPZ equivalent dose in BD, (2) left and right amygdalar SUVR residuals with MCCB emotion regulation and attention T-scores in BD and across the whole sample (BD and CON), and (3) SUVR residuals, MCCB emotion regulation and attention T-scores with volumes of anatomical regions represented in posthoc regions.

All statistical tests other than whole-brain voxelwise analyses were performed using GraphPad Prism version 8.

**Exclusion of controls in whole-brain voxelwise correlation analyses**

No correlations between [11C] Martinostat uptake and MCCB emotion regulation T-scores and MCCB attention T-scores were found across the whole sample (BD and
CON), or between \([^{11}C]Martinostat\) uptake and MCCB attention T-scores in CON in whole-brain voxelwise analyses using FSL’s FEAT (Z > 2.3, \(p_{\text{cluster}} < 0.05\)), with age and sex added to the model as regressors of no interest. The association between \([^{11}C]Martinostat\) uptake and MCCB emotion regulation in CON was previously reported in\(^\text{59}\).

**Results**

**Demographics and clinical characteristics**

Demographic information and cognitive metrics of participants are provided in Table 1 (\(n = 11\) participants per group). No differences in age, sex, body mass index (BMI), smoking status, parental socioeconomic status\(^65\), or cognitive performance as assessed by the MCCB were detected between groups. Information on parental socioeconomic status and handedness was not available for 2 CON because they were from a study that did not inquire this information. The injected \([^{11}C]Martinostat\) dose was significantly different between BD and CON. As injected dose is included in the calculation of SUV, and whole-brain normalization which removes inter-individual differences in global signal was used to calculate SUVR, a 6% difference in injected dose across the two groups will not impact between-group differences. Medication usage of participants with BD is detailed in Supplementary Table 1.

**Region of interest analyses**

To characterize HDAC expression patterns between BD and CON, simultaneous MR-PET was performed with \([^{11}C]Martinostat\), a radiotracer selective for HDAC paralogs 1, 2, 3, and putatively 6\(^39,41\). \([^{11}C]Martinostat\) uptake was measured using SUVR from 60 to 90 min post radiotracer injection. SUVR was lower in the right amygdala of BD compared to CON with a 7.2% mean percentage difference (\(U = 27, p = 0.03\), Fig. 1). The difference in SUVR in the left amygdala was not statistically significant between groups (\(U = 35, p = 0.10\)). SUVR in the left and right amygdala did not correlate with motion estimates in BD and CON (left amygdala: Spearman’s \(r = 0.25, p = 0.26\); right amygdala: Spearman’s \(r = 0.04, p = 0.86\)). There were no subjects identified as outliers using the ROUT method in GraphPad Prism. The volumes of the left and right amygdala in native space were not significantly different between groups (left: \(U = 47, p = 0.40\); right: \(U = 49, p = 0.48\)). SUVR in the DLPFC was not significantly different between groups (\(U = 41, p = 0.22\), Supplementary Fig. 1) and did not correlate with motion estimates in BD and CON (Spearman’s \(r = -0.10, p = 0.67\)).

**Analyses of potential effects of medication**

SUVR in the right amygdala of participants with BD was not related to lithium or lamotrigine prescription (\(U = 9, p = 0.33\), Supplementary Fig. 2a). SUVR in the right amygdala of participants with BD was not related to CPZ equivalent dose (Spearman’s \(r = -0.06, p = 0.85\)). SUVR in the right amygdala did not differ between participants with BD 1 or BD 2 (\(U = 13, p = 0.79\), Supplementary Fig. 2b).

**Exploratory voxelwise analysis**

In a whole-brain voxelwise comparison of SUVR between groups (Z > 2.3, \(p_{\text{cluster}} < 0.05\)), participants with BD showed lower regional uptake in the bilateral thalamus, orbitofrontal cortex, right hippocampus, and right amygdala compared to CON (Fig. 2). No area showed higher SUVR in BD compared to CON. The volumes of these regions were not different between groups in native space (\(U = 43, p = 0.27\)). No between-group differences were found in the volumes of total gray matter (\(U = 53, p = 0.65\)), white matter (\(U = 40, p = 0.19\)) or cerebrospinal fluid (\(U = 48, p = 0.44\)).

**Correlations between cognition and \([^{11}C]Martinostat\) uptake**

**Emotion regulation**

There was no group difference in MCCB emotion regulation T-scores between BD and CON (Table 1). There was no association between SUVR in the left or right amygdala a priori ROIs and emotion regulation in BD (left: Spearman’s \(r = 0.03, p = 0.93\); right: Spearman’s \(r = 0.25, p = 0.46\)). In an exploratory whole-brain voxelwise analysis, higher SUVR in the right prefrontal white matter and left perisylvian region were associated with higher emotion regulation scores in BD (Z > 2.3, \(p_{\text{cluster}} < 0.05\); Supplementary Fig. 3); the volumes of these regions were not correlated to SUVR in native space. Additionally, lower SUVR in the right middle frontal gyrus was associated with higher emotion regulation scores in BD,
however, smaller volume was associated with lower SUVR (Spearman’s $r = 0.67$, $p = 0.03$) and higher emotion regulation (Spearman’s $r = -0.70$, $p = 0.02$) in native space.

**Attention**

There was no group difference in MCCB attention T-scores between BD and CON (Table 1). There was no association between SUVR in the left or right amygdala a priori ROIs and attention in BD (left: Spearman’s $r = -0.46$, $p = 0.16$, right: Spearman’s $r = 0.16$, $p = 0.63$). In an exploratory whole-brain voxelwise analysis, higher SUVR in the bilateral hippocampus and pons, right parahippocampal gyrus, left pallidum and inferior longitudinal fasciculus (temporal regions) were associated with higher attention scores; and lower SUVR in the left middle frontal gyrus, pre- and postcentral gyrus, inferior parietal lobule, and lateral occipital cortex (fronto-parietal regions) were associated with higher attention scores in BD ($Z > 2.3$, $p_{\text{cluster}} < 0.05$; Supplementary Fig. 4). Posthoc assessments of volume showed no correlations between attention and volume (temporal regions: Spearman’s $r = 0.35$, $p = 0.30$; fronto-parietal regions: Spearman’s $r = -0.54$, $p = 0.09$), or between SUVR and volume (temporal regions: Spearman’s $r = 0.50$, $p = 0.13$; fronto-parietal regions: Spearman’s $r = 0.38$, $p = 0.25$).

**Discussion**

BD is characterized by recurrent episodes of altered mood involving disruptions in emotion regulation and cognitive processes which lead to overall functional impairment. A number of structural, functional, and molecular neuroimaging studies implicate aberrant fronto-limbic neural circuitry in BD, however, the molecular mechanisms underlying structural and functional alterations are not fully understood. In this study we used $[^{11}\text{C}]$Martinostat PET to measure and compare relative HDAC expression levels in BD and CON because epigenetic mechanisms, such as those regulated by HDACs, have the potential to reconcile contributions of both genetic and environmental factors in neuropsychiatric disorders including BD. Our primary results indicate lower relative HDAC expression in the right amygdala of BD, as well as within a broader fronto-limbic distribution including the thalamus, orbitofrontal cortex, and hippocampus. Moreover, relative HDAC expression was related to attention and emotion regulation selectively in BD. These results suggest a potential role for HDACs in the fundamental pathophysiology of BD as well as in a subset of its hallmark clinical features.

Consistent with our hypothesis, $[^{11}\text{C}]$Martinostat SUVR was lower in the right amygdala of BD compared to CON. Comparatively, relative HDAC expression was not found to differ in the amygdala of individuals with schizophrenia (SCZ) or schizoaffective disorder (SAD) compared to CON in a prior PET study. Additionally, relative HDAC expression was lower in the DLPFC, a brain region relevant to the pathophysiology of SCZ in a previous study using $[^{11}\text{C}]$Martinostat in SCZ/SAD, but not in the current study of BD, results that further align with post-mortem data. These observations suggest that lower relative HDAC expression in the right amygdala may be a specific etiological feature of BD. The group difference in SUVR of the left amygdala approached but did not reach significance and may be consistent with the hemispheric asymmetry hypothesis of BD, which implicates altered right hemisphere brain function in bipolar depression. However, this result could reflect a limit in statistical power to detect medium effect sizes in the current sample.

Exploratory whole-brain voxelwise analyses detected lower relative HDAC expression in BD compared to CON including the right amygdala and hippocampus, bilateral
thalamus, and orbito-frontal cortex. The amygdala, hippocampus, thalamus, and orbito-frontal cortex are involved in mood regulation, sensory integration, and decision making, which are frequent clinical presentations in patients with BD. In particular, our finding in the thalamus is primarily in the medio-dorsal thalamus, which is involved in cognitive processes and attention, likely due to its dense connections to the prefrontal cortex. The medio-dorsal thalamus has been found to be under-connected to the prefrontal cortex in both patients with BD and schizophrenia using resting state functional MR imaging. Moreover, fronto-limbic regions were previously shown to be abnormal in BD via structural, functional, and molecular neuroimaging studies as mentioned above, providing support to the hypothesis that altered HDAC expression may contribute to the observed regional abnormalities. To date, concordance between HDAC function in BD and the neural circuitry underlying behavior has only been indirectly extrapolated across different postmortem and rodent studies. Use of [11C] Martinostat PET begins to fill this gap by identifying altered HDAC levels in participants with BD in vivo and also offers the unique advantage of possible application during simultaneous functional MR imaging, which should be undertaken in future studies to further dissect the potential impact of altered HDAC levels on neural circuitry in BD. Furthermore, it would be interesting to consider anatomical subregions moving forward. For instance, HDAC inhibition in the basolateral amygdala enhances memory consolidation in rats. The investigation of amygdalar subnuclei may provide more insight into the molecular mechanism of HDAC regulation in relation to cognitive function in BD.

HDACs regulate genes important for activity-dependent regulation of neuroplasticity, as well as genes associated with BD. Therefore, it is possible that altered HDAC expression may contribute to emotional or cognitive disturbances characteristic of BD through altered neuroplasticity. In this study, we explored whether relative HDAC expression levels correlate with emotion regulation and attention. Whole-brain analyses revealed that SUVR was associated with MCCB emotion regulation performance, selectively in BD and within brain regions that have relevance to emotion regulation. Specifically, the left perisylvian region is implicated in language comprehension, the superior temporal sulcus in multiple social processes, including theory of mind, and the middle frontal gyrus in social judgment. These correlates of emotion regulation in BD differ from those identified in healthy participants (e.g. the inferior longitudinal and fronto-occipital fasciculus and hippocampus), raising the possibility that differential regional patterns of HDAC expression may underlie emotion dysregulation in BD. Additionally, lower SUVR in fronto-parietal regions and higher SUVR in temporal regions were correlated with higher attention scores in BD. Sustained attention is typically supported by engagement of fronto-parietal circuitry and deactivation of temporo-limbic regions, including the parahippocampal gyrus. Given that a delicate balance of these two cognitive processes is likely needed for sustained attention, altered relative HDAC expression in these brain regions in BD may contribute to differences in sustained attention. Overall, our results suggest that altered relative HDAC expression in BD may have impacts on emotion regulation and attention.

We acknowledge several limitations of this work. Our study measures differences in [11C]Martinostat uptake relative to the whole-brain mean (SUVR) and not absolute uptake values. Therefore, future [11C]Martinostat PET studies with arterial blood sampling in larger sample sizes will be necessary to validate HDAC expression differences in BD. Given substantial cognitive heterogeneity in BD, the modest sample size of this study may explain why we did not see differences in cognitive performance at the group level. Another possibility is that the participants with BD in this study are more high-functioning to be able to complete a 90-min PET scan, therefore these results may not be generalizable to all patients with BD. Furthermore, participants with BD were medicated and we do not have standardized rating scales of their mood symptoms at the time of the scan. Therefore, future studies with more narrowly defined cohorts of participants with BD, including first-episode patients with limited medication exposure are needed to assess the potential impact of medication status on HDAC expression levels. Despite these limitations, we did test potential confounding factors such as anatomical volumes and potential effects of medication, and our findings were robust to these issues. Nonetheless, a larger sample size will be needed to confirm our findings.

In conclusion, our study presents the first in vivo evidence of altered relative HDAC expression in fronto-limbic regions between participants with BD and age- and sex-matched healthy CON. This work suggests a potential link between altered HDAC expression, attention, and emotion dysregulation in BD.

Acknowledgements

We thank A. Kendall and N. Nortelus for medical coverage; J. Sore and the radiopharmacy team for radiotracer synthesis; G. Arabasz, S. Hsu, and R. Butterfield for assistance with MR-PET imaging; and A. Zhu and M. Hibert for imaging data collection. This research received funding from the National Institute of Mental Health (R21 MH1197101A1 to J.M.H.), Brain and Behavior Research Foundation Independent Investigator Award (J.M.H.) and Young Investigator Award (T.M.G.), MGH Research Scholar’s Program (J.M.H.), MGH ECOR Fund for Medical Discovery (T.M.G.), and Athinoula A. Martinos Center Postdoctoral Pilot Funding (T.M.G.). A.T.P was supported by NIMH T32 MH 112485. This research was carried out at the Athinoula A. Martinos Center for Biomedical Imaging at MGH, using resources provided by the Center for Functional Neuroimaging Technologies, P41EB015896, a P41 Biotechnology Resource Grant supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB),
and the Neuroimaging Analysis Center, P14EB015902, a P41 supported by NIBIB. This work also involved the use of instrumentation supported by the National Institutes of Health (NIH) Shared Instrumentation Grant Program; specifically, S10RR017208-01A1, S10RR026666, S10OR022976, S10OR019933, S10OR023043, and S10OR023401.

Author details
1 Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. 2 Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. 3 Department of Psychiatry, Boston University School of Medicine, Boston, MA 02118, USA. 4 Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Author contributions
T.M.G., C.-E.J.T., B.G.H., A.T.P., N.R.Z., M.C.C., and J.M.H. designed the study. T.M.G., B.G.H., M.C.C., A.J.P., M.K., C.W., J.L.R., H.E.B., and R.H.P. collected human imaging data. T.M.G., B.G.H., M.C.C., A.T.P., and N.R.Z. analyzed human imaging data. C.-E.J.T. and N.R.Z. performed statistical analyses. T.M.G., C.-E.J.T., M.C.C., A.T.P., N.R.Z., and J.M.H. wrote the manuscript. All authors edited the manuscript.

Data availability
The data that support these findings are available from the corresponding author, J.M.H., upon reasonable request. Human subject data will be deidentified to protect confidentiality.

Code availability
Custom codes for PET and MR data processing are available from the corresponding author, J.M.H., upon reasonable request.

Conflict of interest
The content is solely the responsibility of the authors and does not necessarily reflect the official views of Massachusetts General Hospital, Harvard University, and its affiliated academic healthcare centers, or the NIH. Intellectual property (IP) has been filed around [11C]Martinostat by J.M.H. and C. W.; a portion of this IP has been licensed. J.M.H. is a co-founder and equity holder of Eikonizo Therapeutics, Inc. and has received honoraria for speaking or advisory service at non-profit academic institutions. In the past year, J.M.H. has consulted for Psy Therapeutics, Inc., Amathus Therapeutics Inc., Evclo Biosciences Inc., Rodin Therapeutics Inc., and the Alzheimer’s Drug Discovery Foundation. T.M.G. is a current employee of Eikonizo Therapeutics, Inc. The remaining authors declare no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41398-020-00911-5).

Received: 29 May 2020 Revised: 11 June 2020 Accepted: 18 June 2020 Published online: 08 July 2020

References
1. Angst, J. Bipolar disorders in DSM-5: strengths, problems and perspectives. Int. J. Bipolar Disord. 1, 1–3 (2013).
2. McGuffin, P. et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry 60, 497–502 (2003).
3. Keren, B. Genetics of bipolar disorder. Appl. Clin. Genet. 7, 33–42 (2014).
4. Johansson, V., Kuja-Halkola, R., Cannon, T. D., Hultman, C. M. & Hedman, A. M. A population-based heritability estimate of bipolar disorder - In a Swedish twin sample. Psychiatry Res. 278, 180–187 (2019).
5. Aldinger, F. & Schulte, T. G. Environmental factors, life events, and trauma in the course of bipolar disorder. Psychiatry Clin. Neurosci. 71, 6–17 (2017).
6. Tsankova, N., Renthal, W., Kumar, A. & Nestler, E. J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355–367 (2007).
7. Nestler, E. J., Peña, C. J., Kundakovic, M., Mitchell, A. & Alkabian, S. Epigenetic basis of mental illness. Neuroscientist 22, 447–463 (2016).
8. Xiang, B. et al. Systematic genetic analyses of genome-wide association study data reveal an association between the key nuclearosome remodeling and deacetylation complex and bipolar disorder development. Bipolar Disord. 20, 370–380 (2018).
9. Phiel, C. J. et al. Histone deacetylation is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734–36741 (2001).
10. Wu, S. et al. Lithium down-regulates histone deacetylase 1 (HDAC1) and induces degradation of mutant huntingtin. J. Biol. Chem. 288, 35604–35616 (2013).
11. Leng, Y., Fessler, E. B. & Chuang, D. M. Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: Roles of chromatin remodelling and Bcl-2 induction. Int. J. Neuropsychopharmacol. 16, 607–620 (2013).
12. Arent, C. O. et al. Neuroanatomical profile of antimanic effects of histone deacetylases inhibitors. Mol. Neurobiol. 43, 207–214 (2011).
13. Moretti, M. et al. Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behav. Pharmacol. 22, 760–772 (2011).
14. Schroeder, F. A. et al. Expression of HDAC2 but Not HDAC1 transcript is reduced in dorsolateral prefrontal cortex of patients with schizophrenia. ACS Chem. Neurosci. 8, 662–668 (2017).
15. Benes, F. M. et al. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl Acad. Sci. USA 104, 10164–10169 (2007).
16. Kwon, B. & Houpt, T. A. Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. Brain Res. 1333, 36–47 (2010).
17. Valati, F. et al. Administration of a histone deacetylase inhibitor into the basolateral amygdala enhances memory consolidation, delays extinction, and increases hippocampal BDNF levels. Front. Pharmacol. 8, 1–8 (2017).
18. Phillips, M. & Swartz, H. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and roadmap for future research Mary. Am. J. Psychiatry 177, 629–894 (2014).
19. Strakowski, S. M. et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 14, 313–325 (2012).
20. Korgoń, M. et al. Amygdala activation and connectivity to emotional processing distinguishes asymptomatic patients with bipolar disorders and unipolar depression. Biol. Psychiatry 85, 361–370 (2019).
21. Davis, M. & Whalen, P. J. The amygdala: vigilance and emotion. Mol. Psychiatry 6, 13–34 (2001).
22. Costafreda, S. G., Brammer, M. J., David, A. S. & Fu, C. H. Y. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain Res. Rev. 58, 57–70 (2008).
23. Bora, E., Forinto, A., Yucel, M. & Pantelis, C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Bipolar Disord. 17, 1097–1105 (2015).
24. Chen, C. H., Suckling, J., Lennox, B. R., Ooi, C. & Bullmore, E. T. A quantitative meta-analysis of fMRI studies in bipolar disorder. Bipolar Disord. 13, 1–15 (2011).
25. Henny, C. et al. Emotional dysfunction as a marker of bipolar disorders. Front. Biosci. 4, 2622–2630 (2012).
26. Quraishi, S. & Frangou, S. Neuropsychology of bipolar disorder: a review. J. Affect. Disord. 72, 209–226 (2002).
27. Geddes, J. R. & Mckowtiz, D. J. Treatment of bipolar disorders. Lancet 381, 1672–1682 (2013).
28. Fukuda, M. et al. Loss of deacetylation activity of Hdad6 affects emotional behavior in mice https://doi.org/10.1371/journal.pone.0208024 (2012).
29. Anish, K. et al. Altered attentional processing in male and female rats in a preortal valproic acid and exposure model of autistic spectrum disorder. Autism Res. 10, 1929–1944 (2017).
30. Tremolizzo, L. et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol. Psychiatry 57, 500–509 (2005).
31. Schroeder, F. A. et al. A selective HDAC 1/2 inhibitor modulates chomatrin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE 8, e71323 (2013).
32. Jakovcevski, M. et al. Prefrontal cortical dysfunction after overexpression of histone deacetylase 1. Biol. Psychiatry 74, 696–705 (2013).
33. Graff, J. et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222–226 (2012).
34. Guan, J. S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55–60 (2009).
35. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M. & Tsai, L. H. Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178–182 (2007).
36. Gilbert, T. M. et al. PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. J. Clin. Invest 129, 364–372 (2018).
37. Gilbert, T. M. et al. Neuroepigenetic signatures of age and sex in the living human brain. Nat. Commun. 10, 2945 (2019).
38. Schoedel, F. A. et al. PET imaging demonstrates histone deacetylase target engagement and clarifies brain penetration of known and small molecule inhibitors in rat. ACS Chem. Neurosci. 5, 1055–1062 (2014).
39. Wang, C. et al. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. J. Med. Chem. 57, 7999–8009 (2014).
40. Wey, H.-Y. et al. Kinetic analysis and quantification of [11C]Martinostat for 11C HDAC imaging of the brain. ACS Chem. Neurosci. 6, 708–715 (2015).
41. Calgiur, M. P. et al. A functional magnetic resonance imaging study of cortical asymmetry in bipolar disorder. Bipolar Dis. 6, 183–196 (2004).
42. Nuechterlein, K. H. et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165, 203–213 (2008).
43. Kern, R. et al. The relationship between cognitive dysfunction and symptom dimensions across schizophrenia, bipolar disorder, and major depressive disorder. Front. Psychol. 10, 1–8 (2019).
44. Bo, Q. et al. Use of the MATRICS consensus cognitive battery (MCCB) to evaluate cognitive deficits in bipolar disorder: a systematic review and meta-analysis. PLOS ONE 12, 176212 (2017).
45. Motsalay, H. J. & Brown, R. E. Detecting outliers when fitting data with non-linear regression – a new method based on robust nonlinear regression and the false discovery rate. BMC Biom. 7, 123 (2006).
46. Woods, S. W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin Psychiatry 64, 663–667 (2003).
47. Kolb, A. et al. Technical performance evaluation of a human brain PET/MRI system. Eur. Radiol. 22, 1776–1782 (2012).
48. Tisdall, M. D. et al. Volumetric navigators for prospective motion correction and selective reacquisition in neuroanatomical MR. Magn. Reson. Med. 68, 389–399 (2012).
49. Mayer, J. D., Salovey, P., Caruso, D. R. & Sterienos, G. Measuring emotional intelligence with the MSCEIT V2.0. Emotion 3, 97–105 (2003).
50. Cornblatt, B. A., Risch, N. J., Fairis, G., Friedman, D. & Erlenemeyer-Kimling, L. The continuous performance test, identical pairs version (CPT-I): I. new findings about sustained attention in normal families. Psychiatry Res. 26, 223–238 (1988).
51. Clark, L. & Goodwin, G. M. State- and trait-related deficits in sustained attention in bipolar disorder. Eur. Arch. Psychiatr. Clin. Neurosci. 254, 61–68 (2004).
52. McCleary, A. et al. Longitudinal stability of social cognition in schizophrenia: a 5-year follow-up of social perception and emotional processing. Schizophr. Res. 176, 467–472 (2016).
53. Fisch, B. et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuro 33, 341–355 (2002).
54. Hilbar, D. P. et al. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGVA Bipolar Disorder Working Group. Mol. Psychiatry 21, 192–202 (2016).
55. Hilbar, D. P. et al. Subcortical volumetric abnormalities in bipolar disorder. Mol. Psychiatry 21, 1710–1716 (2016).
56. Izquierdo-Garcia, D. et al. An SPMI-based approach for attenuation correction combining segmentation and nonrigid template formation: application to simultaneous PET/MRI brain imaging. J. Nucl. Med. 55, 1825–1830 (2014).
57. Chonde, B., Izquierdo-Garcia, D., Cher, K., Bowen, S. L. & Catania, C. Nisamune: a tool for automatic dynamic PET data processing, image reconstruction and integrated PET/MRI data analysis. EJNMMI Phys. 1, A57 (2014).
58. Keener, M. T. & Phillips, M. L. Neuroimaging in bipolar disorder: a critical review of current findings. Curr. Psychiatry Rep. 9, 512–520 (2007).
59. Greve, D. N. et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage 92, 225–236 (2014).
60. Greve, D. N. et al. Different partial volume correction methods lead to different conclusions: an 18 F-FDG PET study of aging dogus. Neuroimage 132, 334–343 (2016).
61. Smith, S. M. et al. Advances in functional and structural MRI image analysis and implementation as FSL. Neuroimage 23, 5208–5219 (2004).
62. Hollingshead, A. Four Factor Index of Social Status. Unpublished manuscript (Yale University, New Haven, CT, USA, 1975).
63. Townsend, J. & Althuler, L. L. Emotion processing and regulation in bipolar disorder: a review. Bipolar Disord. 14, 326–339 (2012).
64. Penny, A., Roberts, G., Mitchell, P. B. & Breakspear, M. Connectomics of bipolar disorder: a critical review, and evidence for dynamic instabilities within interconnected networks. Mol. Psychiatry 24, 1296–1318 (2019).
65. Drevets, W. C. et al. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol. Biochem. Behav. 71, 431–438 (1999).
66. Ketter, T. A. et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol. Psychiatry 49, 97–109 (2001).
67. Suhara, T. et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 106, 14–18 (1992).
68. Okuno, M. A. et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch. Gen. Psychiatry 64, 201–208 (2007).
69. Harmon-Jones, E. & Gable, P. A. On the role of asymmetric frontal cortical activity in approach and withdrawal motivation: an updated review of the evidence. Psychophysiology https://dx.doi.org/10.1111/j.1469-8986.2010.01287.x (2010).
70. Price, J. L. & Drevets, W. C. Neurocircuitry of mood disorders. Neuropsychopharmacology 35, 192–216 (2010).
71. Mitchell, A. & Chakraborty, S. What does the mediothalamus do? Front. Syst. Neurosci. 7, 37 (2013).
72. Salgado-Pineda, P. et al. Decreased cerebral activation during CPT performance: structural and functional deficits in schizophrenic patients. Neuroimage 21, 840–847 (2004).
73. Ouhaz, Z., Fleming, H. & Mitchell, A. S. Cognitive functions and neurodevelopmental disorders involving the prefrontal cortex and medialdorsal thalamus. Front. Neurosci. 12, 33 (2018).
74. Anticevic, A. et al. Characterizing thalamo-cortical disturbances in schizophrenia and bipolar illness. Cereb. Cortex 24, 3116–3130 (2013).
75. Bahar-Banai, S. et al. HDAC1 regulates fear extinction in mice. J. Neuroscience 32, 5062–5073 (2012).
76. Hagarty, S. J. & Tsai, L.-H. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol. Learn. Mem. 96, 41–52 (2011).
77. Simonini, M. V. et al. The benzamide MS-275 is a potent, long-lasting brain cetylase inhibitors and candidate gene expression: an in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J. Psychiatry 43, 870–876 (2009).
78. Koenigs, M. et al. Areas of left perisylvian cortex mediate auditory-verbal short-term memory. Neuropsychology 49, 3612–3619 (2011).
79. Beauchamp, M. S. The social mysteries of the superior temporal sulcus. Trends Cogn. Sci. 19, 489–490 (2015).
80. Mulhjeeve, P. et al. Altered amygdala connectivity within the social brain in schizophrenia. Schizophr. Bull. 40, 152–160 (2013).
81. Lawrence, N. S., Ross, T. J., Hoffmann, R., Garavan, H. & Stein, E. A. Multiple neuronal networks mediate sustained attention. J. Cogn. Neurosci. 15, 1028–1038 (2003).